Home Search
viaskin - search results
If you're not happy with the results, please do another search
Private Law Firm to Investigate Claims on Behalf of Investors in DBV Technologies
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by Summer 2023
The market for epinephrine delivery may expand to include non-needle alternatives next year.
New Microneedle Patch Therapy for Food Allergies Takes Step Forward
Painless microneedle patch may provide new method for desensitization.
DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and Eggs, to Lay...
The company announced they would be laying off 200 employees in Q1.
Company Developing Therapy to Prevent “Allergic Cascade” Emerges from Stealth Mode
IgGenix will develop a therapy that focuses on all types of food allergies and related conditions.
FAQ for Palforzia, the First FDA Approved Therapy for Food Allergy
What it is, what it treats, who it is for, how it is used, et al.
SnackSafely.com Newsletter: 2019/08/08
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut for the Treatment of Peanut Allergy (+4 Articles)
Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies
FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
Asthma and Allergy Foundation of America Responds to Premature ICER Review of New Peanut...
The AAFA addresses concerns
regarding the Final Evidence Report released by the ICER.
ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not Yet Demonstrate That...
The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).